Home › NDC Lookup › Ingredients › Tocilizumab-Aazg
📦 NDC / package directory — not a drug information page

Tocilizumab-Aazg NDCs, Package Codes, Strengths & Labelers

This page lists NDC package records for Tocilizumab-Aazg products — strengths, dosage forms, package sizes, labelers, 11-digit billing NDCs, pricing data when available, and links to each individual NDC page. It’s an NDC/package & billing directory, not a clinical drug page.

Key stats

7
Package NDCs
14
Products
14
Active listings
0
Discontinued
1
Labelers
4
Strengths
2
Dosage forms
2
With NADAC pricing

By strength, form & labeler

NDC products by strength
TOCILIZUMAB 162 mg/.9mL 8
TOCILIZUMAB 200 mg/10mL 2
TOCILIZUMAB 400 mg/20mL 2
TOCILIZUMAB 80 mg/4mL 2
By dosage form
INJECTION, SOLUTION 8
INJECTION, SOLUTION, CONCENTRATE 6
Top labelers
Fresenius Kabi USA, LLC 14

Browse records — 14 products

Drug / product Billing NDC NADAC / unit Status
TYENNE Tocilizumab-aazg 162 mg/.9mL INJECTION, SOLUTION Fresenius · NDC 65219-0584-01 · Q5135 · 1 SYRINGE, GLASS in 1 CARTON (65219-584-01) / .9 mL in 1 SYRINGE, GLASS 65219-0584-01 $820.997 /unit · NADAC On market View →
TYENNE Tocilizumab-aazg 162 mg/.9mL INJECTION, SOLUTION Fresenius · NDC 65219-0598-10 · 1 SYRINGE, GLASS in 1 CARTON (65219-598-10) / .9 mL in 1 SYRINGE, GLASS 65219-0598-10 — On market View →
TYENNE Tocilizumab-aazg 162 mg/.9mL INJECTION, SOLUTION Fresenius · NDC 65219-0586-04 · Q5135 · 1 SYRINGE, GLASS in 1 CARTON (65219-586-04) / .9 mL in 1 SYRINGE, GLASS 65219-0586-04 — On market View →
TYENNE Tocilizumab-aazg 200 mg/10mL INJECTION, SOLUTION, CONCENTRATE Fresenius · NDC 65219-0592-10 · Q5135 · 1 VIAL, SINGLE-DOSE in 1 CARTON (65219-592-10) / 10 mL in 1 VIAL, SINGLE-DOSE 65219-0592-10 — On market View →
TYENNE Tocilizumab-aazg 162 mg/.9mL INJECTION, SOLUTION Fresenius · NDC 65219-0596-01 · 1 SYRINGE, GLASS in 1 CARTON (65219-596-01) / .9 mL in 1 SYRINGE, GLASS 65219-0596-01 $820.997 /unit · NADAC On market View →
TYENNE Tocilizumab-aazg 400 mg/20mL INJECTION, SOLUTION, CONCENTRATE Fresenius · NDC 65219-0594-20 · Q5135 · 1 VIAL, SINGLE-DOSE in 1 CARTON (65219-594-20) / 20 mL in 1 VIAL, SINGLE-DOSE 65219-0594-20 — On market View →
TYENNE Tocilizumab-aazg 80 mg/4mL INJECTION, SOLUTION, CONCENTRATE Fresenius · NDC 65219-0590-04 · Q5135 · 1 VIAL, SINGLE-DOSE in 1 CARTON (65219-590-04) / 4 mL in 1 VIAL, SINGLE-DOSE 65219-0590-04 — On market View →
TYENNE Tocilizumab-aazg 162 mg/.9mL INJECTION, SOLUTION Fresenius · NDC 65219-0596-01 · 1 SYRINGE, GLASS in 1 CARTON (65219-596-01) / .9 mL in 1 SYRINGE, GLASS 65219-0596-01 $820.997 /unit · NADAC On market View →
TYENNE Tocilizumab-aazg 162 mg/.9mL INJECTION, SOLUTION Fresenius · NDC 65219-0598-10 · 1 SYRINGE, GLASS in 1 CARTON (65219-598-10) / .9 mL in 1 SYRINGE, GLASS 65219-0598-10 — On market View →
TYENNE Tocilizumab-aazg 200 mg/10mL INJECTION, SOLUTION, CONCENTRATE Fresenius · NDC 65219-0592-10 · Q5135 · 1 VIAL, SINGLE-DOSE in 1 CARTON (65219-592-10) / 10 mL in 1 VIAL, SINGLE-DOSE 65219-0592-10 — On market View →
TYENNE Tocilizumab-aazg 80 mg/4mL INJECTION, SOLUTION, CONCENTRATE Fresenius · NDC 65219-0590-04 · Q5135 · 1 VIAL, SINGLE-DOSE in 1 CARTON (65219-590-04) / 4 mL in 1 VIAL, SINGLE-DOSE 65219-0590-04 — On market View →
TYENNE Tocilizumab-aazg 400 mg/20mL INJECTION, SOLUTION, CONCENTRATE Fresenius · NDC 65219-0594-20 · Q5135 · 1 VIAL, SINGLE-DOSE in 1 CARTON (65219-594-20) / 20 mL in 1 VIAL, SINGLE-DOSE 65219-0594-20 — On market View →
TYENNE Tocilizumab-aazg 162 mg/.9mL INJECTION, SOLUTION Fresenius · NDC 65219-0584-01 · Q5135 · 1 SYRINGE, GLASS in 1 CARTON (65219-584-01) / .9 mL in 1 SYRINGE, GLASS 65219-0584-01 $820.997 /unit · NADAC On market View →
TYENNE Tocilizumab-aazg 162 mg/.9mL INJECTION, SOLUTION Fresenius · NDC 65219-0586-04 · Q5135 · 1 SYRINGE, GLASS in 1 CARTON (65219-586-04) / .9 mL in 1 SYRINGE, GLASS 65219-0586-04 — On market View →
Where does this data come from?
NDC package records, strengths, forms and labelers come from the openFDA NDC Directory; pricing is CMS NADAC. Grouped by active-ingredient name. This is package/billing reference data, not clinical drug information.